Lupin receives tentative USFDA approval for a generic cancer medication

30 Aug 2022 , 07:58 AM

The US health agency has given Lupin provisional approval to market Dasatinib tablets, used to treat specific forms of cancer, in the US.

Dasatinib tablets in strengths of 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg have been approved by the US Food and Drug Administration (FDA), the company in collaboration with Pharmascience Inc. stated in a statement.

The medicine produced by the company in Mumbai is a substitute for the Sprycel pills sold by Bristol-Myers Squibb Company.

Dasatinib tablets had an estimated annual sale of USD 1,569 million in the US, according to IQVIA MAT statistics.

On the BSE, Lupin shares ended the day at Rs 662.50 a share, up 1.49%.

For feedback and suggestions, write to us at [e-mail]